BioRestorative Therapies Inc Ordinary Shares BRTX 深 滬
等待開盤 08-08 09:30:00 美东时间
1.43
-0.035
-2.36%
華盛通- 最 高1.48
- 今 開1.48
- 成交量 1.82万股
- 最 低 1.41
- 昨 收 1.4646
- 總市值 1073.19万
- 52周最高 2.55
- 市盈率 靜 --
- 換手率 0.24%
- 52周最低 1.21
- 委 比 27.94%
- 總股本 750.48万
- 歷史最高 8.90
- 量 比 0.65
- 振 幅 4.78%
- 歷史最低 1.03
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025
<p>BioRestorative Therapies, Inc. (NASDAQ: BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, announced it will release its second quarter 2025 financial results after market close on August 12, 2025. A conference call to discuss the results will follow at 4:30 p.m. ET. The call details include domestic toll-free number 1-888-506-0062, international number 1-973-528-0011, and access code 436077. Addit...
08-05 20:30
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates
BioRestorative Therapies, Inc. (BRTX) announced that its CEO, Lance Alstodt, will be interviewed on the Benzinga All-Access Show on June 18, 2025, at 10:50 a.m. ET. The company specializes in stem cell-based therapies, focusing on three clinical programs: BRTX-100 for disc/spine disease, ThermoStem® for metabolic disorders, and BioCosmeceuticals for aesthetic treatments. BRTX-100 is in Phase 2 trials for chronic lower back pain, while ThermoStem®...
06-18 13:35
【TradingKey財經早餐】川普威脅打擊伊朗，油價大漲5%，特斯拉跌4%，光伏股Sunrun暴跌40%；參議院通過穩定幣法案
TradingKey - 6月17日週二，川普威脅軍事介入以伊衝突並呼籲伊朗無條件投降，油價飆升5%，美股全線回落，特斯拉跌4%，受太陽能稅收優惠將逐步取消影響的光伏股Sunrun暴跌40%，腦機接口概念股腦再生科技漲30%。美媒報道稱，川普正越來越有意動用美國軍事資產空襲伊朗核設施；若伊朗作出重大讓步，仍對外交手段保持開放態度。
06-18 00:58
BioRestorative Therapies announces share repurchase program; shares gain over 8%
BioRestorative Therapies (NASDAQ:BRTX) announced on Tuesday that its board of directors has authorized a stock repurchase program to repurchase up to $2 million of its outstanding common stock through...
06-17 21:32
BioRestorative Therapies Announces $2M Stock Repurchase Program
BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that its Board
06-17 21:25
BioRestorative Announces Share Repurchase Program
BioRestorative Therapies, Inc. (BRTX) announced a $2 million stock repurchase program through June 16, 2026, reflecting confidence in its clinical pipeline and future growth. CEO Lance Alstodt cited the company's strong science and assets, stating current share price undervalues its intrinsic worth. Repurchases may occur via open market or private transactions, with management discretion based on market conditions. The program highlights BRTX's f...
06-17 13:25
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
Melville, N.Y., June 13, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. announced promising Phase 2 clinical trial data for BRTX-100, an autologous stem cell therapy for chronic lumbar disc disease (cLDD). Results from the first 36 subjects showed over 74% improvement in function (ODI) and over 72% reduction in pain (VAS) by 52 weeks. No serious adverse events were reported. The data was presented at the ISSCR 2025 Annual Meeting in Hong...
06-13 11:45
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has appointed Sandy Lipkins as Senior Vice President of Technology Commercialization and Business Development. Lipkins, with over 30 years of experience in venture capital, finance, and sales, particularly in the anti-aging and wellness sectors, will focus on strategic alliances, licensing agreements, and expanding the company’s commercial BioCosmeceuticals platform. The company, which specializes in ...
06-10 12:00
BioRestorative to Present Stem Cell Trial Data for Back Pain at Global Conference
BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies for serious musculoskeletal conditions, today
06-09 19:48
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative Therapies, Inc. plans to present preliminary, blinded Phase 2 clinical data from 30 patients treated with BRTX-100 for chronic lumbar disc disease at the ISSCR 2025 Annual Meeting on June 13, 2025, in Hong Kong. The presentation will highlight safety and functional improvement metrics. The Phase 2 trial involves up to 99 patients across 16 U.S. sites, with results expected to be shared publicly prior to market open on June 13. Fran...
06-09 11:45
